Aprepitant for refractory nivolumab-induced pruritus.
Sign Up to like & getrecommendations! Published in 2017 at "Lung cancer"
DOI: 10.1016/j.lungcan.2017.04.020
Abstract: Although substantial progress has been made in the treatment of non-small-cell lung cancer (NSCLC) patients with immune checkpoint inhibitors (ICIs), severe immune-related adverse events (irAEs) sometimes occur. Here, we report a case of severe refractory… read more here.
Keywords: aprepitant refractory; refractory nivolumab; refractory pruritus; pruritus ... See more keywords